

Case Report Volume 3 | issue 3

Crispr-Casg Dna Sequencing with Genome Editing Tool: A New Approach to World Congress on Genome Database Array: A New Approach to Clinical Biomedical Research and Epidemiology

Vivienne Lunde Dadon, Simone Bridgesson and Sydney Trondheim

Lofton Publishing LTD L.P., Arctic Regulations Commission (University of Arctic Industrial Science School of Physics), AIU (School of Business), University of Amsterdam (Metropolitan School of Urban Studies), Boston University School of Bioscience and Law (CLOSED), Island.

***Corresponding Author:** Vivienne Lunde Dadon,, Lofton Publishing LTD L.P., Arctic Regulations Commission (University of Arctic Industrial Science School of Physics), AIU (School of Business), University of Amsterdam (Metropolitan School of Urban Studies), Boston University School of Bioscience and Law (CLOSED). Island.

Submitted: 25 Apr 2025 Accepted: 06 May 2025 Published: 09 May 2025

Citation: Vivienne Lunde Dadon, Simone Bridgesson and Sydney Trondheim (2025). Crispr-Casg Dna Sequencing with Genome Editing Tool: A New Approach to World Congress on Genome Database Array: A New Approach to Clinical Biomedical Research and Epidemiology. J of Clin Case Stu, Reviews & Reports 3(3), 1-3.

Abstract

International Trademark Policy, Immunology and Microscopic Science Organization, International Classification of Disease, and Royale Chemical Society, World Patents on Chemical Molecular Compounds, and Biomedical Vector Control Products.{Figure 1}.

Keywords: Biomedical Systems, Patent on CRISPR-Cas9, Medical Images, Case Studies, Clinical Science, Allied Health, Approaches to Molecular Biological Sciences, Natural Science, Zoology, Microscopic Science, Business and Law adherence to Medical Science, Architecture of DNA, 3D Clinical Design Systems, Genetics and DNA, Ribosomal RNA, CRISPR-Cas, Bacteriology and Epidemiology, Clinical and Therapeutic Applications of CRIPR-/Cas9

Introduction

The New approach to World Congress on Biopharmaceuticals and gene study, has integrated a synchronistic system of precise modifications of DNA sequences in the same Geophysical Regions. Taxonomy of specific were gathered by annuity and placed into newly manufactured AI-Computer Aided Spectrometry (by design). The Business analytics of this newly architected system adheres to biomedical laws, policies by set parameters. It collects data as a cyclical approach, with molecular compounds, biological age, taxonomy, Geospatial Digitial Trademarks and produces a Taxonomy Chart in a Robotic Circuit, and Charts. The CRISPR-Cas9 also has an experimental case study linked to pythons in natural sciences, and ammonia frozen satellite banks with environmental qualities. We will demonstrate in this Dossier the important of this Patent set by Geophysics Experts. {Figure 2} {Bio Chem DNA}



Figure 1: DNA Sequencing, Biomedical Laboratory Images for Diagnostic Tools in DNA Mechanism, locations of proteins and bonds, and enzymes. Also, for Gene Editing Tools in Clinical Data Systems.{Figure 3} { Pharmacol DNA}

Methodology

- 1. Cysteine Protein (Slides and Interpretations) ddPC
- 2. Genetic Molecular Database Informatics
- 3. Blood Tests/Catalyst Analysis (Antibodies)
- 4.Biopharmaceutical Tests for Antibody
- 5. Clinical Therapeutic Application of CRISPR Cas9
- 6. Clinical Therapeutic Application of Cysteine Protein
- 7. Genetic Therapy with Protein Synthesis in DNA Molecule

Experimental Case with Tables and Equations

Initially would like to illustrate how the DNA Protein is coded and analyzed in a chart.

Below {Table 1}, we illustrate the Genetic Sequencing, and codons, in {Table 2} we illustrate the different Genetic Codes in order, and validity. {Biopharma DNA} {Figure 3}

Table 1: Genetic Code and Codon Table. UCAG (1st Letter Matching Mathematical Analysis Equation and Solution to 2nd Letter).

UUU	UCU	UAU	UGU	AGU	AAU	ACU	AUU
UUC	UCC	UAC	UGC	AGC	AAC	ACC	AUC
UUA	UCA	UAA	UGA	AGA	AAA	ACA	AUA
UUG	UCG	UAG	UGG	AGG	AAG	ACG	AUG (<met)< td=""></met)<>





Case 1: Includes the simulation of CRISPR-Cas9 (Antibodies) with Cysteine protease by syndication of Biological Significance. The Cysteine Proteases (protein) has an enzyme that uses the cysteine residue in their active site to catalyze reactions, including the cleavage of the peptide bonds in the proteins (molecular equations includes Peptide- Bond Hydrolases. The formula or equation in Natural Science uses the S- anion of a cysteine side chain as the nucleophile in the peptide bond). The equation for this is +R-CO-NH-R/-R COOH, hydrolases of the peptide bond equation is +H20/-H2N-R. {Table 1} {Pharmacol DNA} {Figure 2}.

Simulation of CRISPR-Cas9 and Rapid Defense of Pathogens with syndication of Cysteine Proteases is for hemoglobin regulations.

- Activators involve catalytic mechanisms of peptide bonds, and hemoglobin regulations.
- ICAD/DFF45 (Inhibitor of DNase) CRISPR-Cas9 (Lofton) both in Patent and Trademark under PCT 522119665.
- Biochemical reactions of this Simulation and Detection of pathogen involves the initiation of CRISPR-Cas9 with syndication of Cysteine Protease in a mechanism of peptide bond and serine proteases. {Figure 2} {DNA Pharmacol}.



Figure 2: Enzymes, DNA, and RNA, with peptide bonds, 3D Interpretation, and 3D Clinical Architecture and Modelling of Microscopic Scientific Data. {Chem DNA}

Case 2: CRISPR- Cas9 and DNA Repair

- Gene Therapeutics with Vector Control Product under Patent and Trademark was placed in Biomedical Clinical Laboratory through a catalyst storage Capsule.
- Activation begins during a molecular bond and "scissor" in biomedical approach, Under a "DNA Cutting Editing Technology". The DNA was then placed in specific
- Locations for (bacteriology/virology studies). The Guide RNA removed the bacteria, And virus from the DNA and bonded to gRNA. The Cas9 enzyme encapsulated the Nucleic Acid (DNA break). This started the DNA repair. {Table 2} {Pharma Sci}
- This guided use to the nuclease protein for the Gene Knockout, were the "cut"
- Was made against viral DNA. {Figure 1}
- The DNA Breaks, CRISPR/Cas9 Enzyme "cuts" the DNA at the target location, then Attaches to gRNA in specific sequence (Biological Medicine/Immune Defense) { Bio Pharma} {Figure 2} D



Figure 3: CRISPR-CasS 3D Model of Enzyme, 3D Ribosomal DNA, 3D Clinical Design in Biological Science Molecular Architecture Labs. Here you see the Enzyme rRNA binding, to DNA, and continued to Cas 12 and Cas 13. {DNA Molecul} {Immuno Toxicol}

Results and Summary of Both Cases

Nanoparticles were used as cellular target modification for next

biomedical clinical case. Biolistic Bombardment is when the nanoparticles are stored for lateral use "particle population Lab" {ATSL Molecule} were burst of gas delivered into the components of CRISPR enzyme produces as particles (virus) disruptions.{Bio Chem} {Figure 3}

Summary and Recommendations

Biomedical Research and Testing with Clinical Cases is important in provided cutting edge innovation into Genetic Therapy for Bacteriology, Plant Protein Degradation (next case report), and Classification of Disease. {New Biology} This article focuses on the crucial roles of the biological processes, as it fits into Clinical Applications, and Clinical Data. The Cysteine Protease is a derivate of snake venom, and simulated with CRISPR-Cas9, we can adhere to Gene Editing, and DNA Repair. In our continued efforts our next articles and case study will incorporate Cas9, Cas12, and Cas13. I recommend continued Research into this Biomedical Science, and Molecular Genetic Editing, and Biopharmaceutical Research. {Bio Chem} {Figure 3}.

Acknowledgement

To original authors of Biomedical Research and Application of Patent Tools and Trademarks.

Conflict of Interest

We are a privately funded laboratory, and we don't provide any open documentation on medical dossier

References

- Author unknown. (1973). Protease inhibitors as snake venom toxins. LISTERSERV.DR2 Immunology and Toxicology. PubMed. https://pubmed.ncbi.nlm.nih.gov/4512962
- Lofton Publishing. (2009). Virology: Cysteine proteins and CRISPR-Cas12. NTNU New Biology, Premier MD Bookshelves, 1(1), Article 1.
- BioLibreTexts. (n.d.). Mechanism of catalysis. Gene Therapy, NICE CXone Expert. https://libretexts.org/Bookshelves/ Biochemistry
- 4. Broad Institute. (n.d.). FDA/Maine University of Biological Science and Law in Q/A CRISPR. Genetic Perturbation Platform, CRISPR Research News, 1.
- 5. Frontiers. (n.d.). Global regulatory landscape of CRISPR Cas9/12/13. Bio Molecul. Neuropathology, 2, Article 33.
- 6. Codexis. (n.d.). Pharma enzyme innovations. Biopharmaceuticals/Clinical Pharmacology, Pharmacol DNA.
- 7. Author unknown. (n.d.). Cysteine protein/CRISPR-gene therapy pharmaceutical solutions. Pharma Sci.

Copyright: ©2025 Vivienne Lunde Dadon. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.